HIV RNA levels in plasma and cervical-vaginal lavage fluid in elite controllers and HAART recipients

Alan Landay, Elizabeth T. Golub, Seema Desai, Jinbing Zhang, Val Winkelman, Kathryn Anastos, Helen Durkin, Mary Young, Maria C. Villacres, Ruth M. Greenblatt, Philip J. Norris, Michael P. Busch

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Objectives: The introduction of HAART leads to control of HIV replication to less than 50 copies/ml, similar to levels in 'elite controllers'. Low-level viral replication may be one of the contributing factors to persistent immune activation/inflammation in HAART-treated individuals. There are still gaps in our knowledge of whether low-level replication persists in systemic versus mucosal sites. Design and methods: Participants for this study were recruited from the Women's Interagency HIV Study. We evaluated 33 'elite controllers' who naturally controlled HIV replication and 33 matched HAART-suppressed recipients. This study employed a sensitive target-capture transcription-mediated- amplification assay to compare low-level virus concentrations in plasma and cervical-vaginal lavage (CVL) samples from HIV-positive HAART recipients and 'elite controllers'. Results: The median (interquartile range) plasma viral load signal/cut-off (S/Co) for 'elite controllers' was 10.5 (3.9-21.1), which was significantly (P<0.001) higher than the S/Co for HAART recipients [2.0 (1-4.9)]. The majority of CVL samples from both groups had undetectable HIV RNA and the proportion of CVL samples with a cut-off more than 1.0 was not different between 'elite controllers' and HAART-suppressed recipients. Conclusion: This study demonstrated persistent low-level HIV replication in 'elite controllers', suggesting potential value of HAART treatment for these individuals. Absent or very low levels of HIV RNA in CVL indicate very low risk of secondary sexual transmission for both groups.

Original languageEnglish (US)
Pages (from-to)739-743
Number of pages5
JournalAIDS
Volume28
Issue number5
DOIs
StatePublished - Mar 13 2014

Fingerprint

Vaginal Douching
Highly Active Antiretroviral Therapy
HIV
RNA
Viral Load
Viruses
Inflammation

Keywords

  • Cervical-vaginal lavage
  • Elite controllers
  • HAART-suppressed patients
  • TMA

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Infectious Diseases
  • Medicine(all)

Cite this

Landay, A., Golub, E. T., Desai, S., Zhang, J., Winkelman, V., Anastos, K., ... Busch, M. P. (2014). HIV RNA levels in plasma and cervical-vaginal lavage fluid in elite controllers and HAART recipients. AIDS, 28(5), 739-743. https://doi.org/10.1097/QAD.0000000000000150

HIV RNA levels in plasma and cervical-vaginal lavage fluid in elite controllers and HAART recipients. / Landay, Alan; Golub, Elizabeth T.; Desai, Seema; Zhang, Jinbing; Winkelman, Val; Anastos, Kathryn; Durkin, Helen; Young, Mary; Villacres, Maria C.; Greenblatt, Ruth M.; Norris, Philip J.; Busch, Michael P.

In: AIDS, Vol. 28, No. 5, 13.03.2014, p. 739-743.

Research output: Contribution to journalArticle

Landay, A, Golub, ET, Desai, S, Zhang, J, Winkelman, V, Anastos, K, Durkin, H, Young, M, Villacres, MC, Greenblatt, RM, Norris, PJ & Busch, MP 2014, 'HIV RNA levels in plasma and cervical-vaginal lavage fluid in elite controllers and HAART recipients', AIDS, vol. 28, no. 5, pp. 739-743. https://doi.org/10.1097/QAD.0000000000000150
Landay, Alan ; Golub, Elizabeth T. ; Desai, Seema ; Zhang, Jinbing ; Winkelman, Val ; Anastos, Kathryn ; Durkin, Helen ; Young, Mary ; Villacres, Maria C. ; Greenblatt, Ruth M. ; Norris, Philip J. ; Busch, Michael P. / HIV RNA levels in plasma and cervical-vaginal lavage fluid in elite controllers and HAART recipients. In: AIDS. 2014 ; Vol. 28, No. 5. pp. 739-743.
@article{f3b51b8bba5249e1ad451ca5907cc303,
title = "HIV RNA levels in plasma and cervical-vaginal lavage fluid in elite controllers and HAART recipients",
abstract = "Objectives: The introduction of HAART leads to control of HIV replication to less than 50 copies/ml, similar to levels in 'elite controllers'. Low-level viral replication may be one of the contributing factors to persistent immune activation/inflammation in HAART-treated individuals. There are still gaps in our knowledge of whether low-level replication persists in systemic versus mucosal sites. Design and methods: Participants for this study were recruited from the Women's Interagency HIV Study. We evaluated 33 'elite controllers' who naturally controlled HIV replication and 33 matched HAART-suppressed recipients. This study employed a sensitive target-capture transcription-mediated- amplification assay to compare low-level virus concentrations in plasma and cervical-vaginal lavage (CVL) samples from HIV-positive HAART recipients and 'elite controllers'. Results: The median (interquartile range) plasma viral load signal/cut-off (S/Co) for 'elite controllers' was 10.5 (3.9-21.1), which was significantly (P<0.001) higher than the S/Co for HAART recipients [2.0 (1-4.9)]. The majority of CVL samples from both groups had undetectable HIV RNA and the proportion of CVL samples with a cut-off more than 1.0 was not different between 'elite controllers' and HAART-suppressed recipients. Conclusion: This study demonstrated persistent low-level HIV replication in 'elite controllers', suggesting potential value of HAART treatment for these individuals. Absent or very low levels of HIV RNA in CVL indicate very low risk of secondary sexual transmission for both groups.",
keywords = "Cervical-vaginal lavage, Elite controllers, HAART-suppressed patients, TMA",
author = "Alan Landay and Golub, {Elizabeth T.} and Seema Desai and Jinbing Zhang and Val Winkelman and Kathryn Anastos and Helen Durkin and Mary Young and Villacres, {Maria C.} and Greenblatt, {Ruth M.} and Norris, {Philip J.} and Busch, {Michael P.}",
year = "2014",
month = "3",
day = "13",
doi = "10.1097/QAD.0000000000000150",
language = "English (US)",
volume = "28",
pages = "739--743",
journal = "AIDS",
issn = "0269-9370",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - HIV RNA levels in plasma and cervical-vaginal lavage fluid in elite controllers and HAART recipients

AU - Landay, Alan

AU - Golub, Elizabeth T.

AU - Desai, Seema

AU - Zhang, Jinbing

AU - Winkelman, Val

AU - Anastos, Kathryn

AU - Durkin, Helen

AU - Young, Mary

AU - Villacres, Maria C.

AU - Greenblatt, Ruth M.

AU - Norris, Philip J.

AU - Busch, Michael P.

PY - 2014/3/13

Y1 - 2014/3/13

N2 - Objectives: The introduction of HAART leads to control of HIV replication to less than 50 copies/ml, similar to levels in 'elite controllers'. Low-level viral replication may be one of the contributing factors to persistent immune activation/inflammation in HAART-treated individuals. There are still gaps in our knowledge of whether low-level replication persists in systemic versus mucosal sites. Design and methods: Participants for this study were recruited from the Women's Interagency HIV Study. We evaluated 33 'elite controllers' who naturally controlled HIV replication and 33 matched HAART-suppressed recipients. This study employed a sensitive target-capture transcription-mediated- amplification assay to compare low-level virus concentrations in plasma and cervical-vaginal lavage (CVL) samples from HIV-positive HAART recipients and 'elite controllers'. Results: The median (interquartile range) plasma viral load signal/cut-off (S/Co) for 'elite controllers' was 10.5 (3.9-21.1), which was significantly (P<0.001) higher than the S/Co for HAART recipients [2.0 (1-4.9)]. The majority of CVL samples from both groups had undetectable HIV RNA and the proportion of CVL samples with a cut-off more than 1.0 was not different between 'elite controllers' and HAART-suppressed recipients. Conclusion: This study demonstrated persistent low-level HIV replication in 'elite controllers', suggesting potential value of HAART treatment for these individuals. Absent or very low levels of HIV RNA in CVL indicate very low risk of secondary sexual transmission for both groups.

AB - Objectives: The introduction of HAART leads to control of HIV replication to less than 50 copies/ml, similar to levels in 'elite controllers'. Low-level viral replication may be one of the contributing factors to persistent immune activation/inflammation in HAART-treated individuals. There are still gaps in our knowledge of whether low-level replication persists in systemic versus mucosal sites. Design and methods: Participants for this study were recruited from the Women's Interagency HIV Study. We evaluated 33 'elite controllers' who naturally controlled HIV replication and 33 matched HAART-suppressed recipients. This study employed a sensitive target-capture transcription-mediated- amplification assay to compare low-level virus concentrations in plasma and cervical-vaginal lavage (CVL) samples from HIV-positive HAART recipients and 'elite controllers'. Results: The median (interquartile range) plasma viral load signal/cut-off (S/Co) for 'elite controllers' was 10.5 (3.9-21.1), which was significantly (P<0.001) higher than the S/Co for HAART recipients [2.0 (1-4.9)]. The majority of CVL samples from both groups had undetectable HIV RNA and the proportion of CVL samples with a cut-off more than 1.0 was not different between 'elite controllers' and HAART-suppressed recipients. Conclusion: This study demonstrated persistent low-level HIV replication in 'elite controllers', suggesting potential value of HAART treatment for these individuals. Absent or very low levels of HIV RNA in CVL indicate very low risk of secondary sexual transmission for both groups.

KW - Cervical-vaginal lavage

KW - Elite controllers

KW - HAART-suppressed patients

KW - TMA

UR - http://www.scopus.com/inward/record.url?scp=84898011439&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84898011439&partnerID=8YFLogxK

U2 - 10.1097/QAD.0000000000000150

DO - 10.1097/QAD.0000000000000150

M3 - Article

VL - 28

SP - 739

EP - 743

JO - AIDS

JF - AIDS

SN - 0269-9370

IS - 5

ER -